Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
59.93
-0.25 (-0.42%)
At close: May 16, 2025, 4:00 PM
59.70
-0.23 (-0.38%)
After-hours: May 16, 2025, 4:51 PM EDT
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 283 employees as of December 31, 2024. The number of employees increased by 57 or 25.22% compared to the previous year.
Employees
283
Change (1Y)
57
Growth (1Y)
25.22%
Revenue / Employee
$483,615
Profits / Employee
-$614,912
Market Cap
3.81B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
RYTM News
- 3 days ago - Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program - GlobeNewsWire
- 9 days ago - Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 11 days ago - Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 24 days ago - Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - GlobeNewsWire
- 5 weeks ago - Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder - Seeking Alpha
- 5 weeks ago - Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - Reuters
- 5 weeks ago - Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewsWire